New drug ADX-038 aims to control anemia in PNH patients
NCT ID NCT05876312
First seen Jan 25, 2026 · Last updated May 16, 2026 · Updated 21 times
Summary
This study tests a new drug called ADX-038 for people with PNH who still have anemia despite treatment. It first checks safety in healthy adults, then tests the drug in PNH patients. The goal is to see if ADX-038 can safely control the disease and improve red blood cell health.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, PNH are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Nucleus Network Brisbane
ACTIVE_NOT_RECRUITINGBrisbane, Queensland, 4006, Australia
-
Peter MacCallum Cancer Centre
NOT_YET_RECRUITINGMelbourne, Victoria, 3000, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Richmond Pharmacology Ltd
ACTIVE_NOT_RECRUITINGLondon, SE1 1YR, United Kingdom
-
Royal Melbourne Hospital
RECRUITINGParkville, Victoria, 3052, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.